Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa

Objective:To assess the performance of WHO clinical and CD4 cell count criteria for antiretroviral treatment (ART) failure among HIV-infected adults in a workplace HIV care programme in South Africa. Design:Cohort study. Methods:We included initially ART-naive participants who remained on first-line therapy and had an evaluable HIV viral load result at the 12-month visit. WHO-defined clinical and CD4 cell count criteria for ART failure were compared against a gold standard of virological failure. Results:Among 324 individuals (97.5% men, median age 40.2, median starting CD4 cell count and viral load 154 cells/μl and 47 503 copies/ml, respectively), 33 (10.2%) had definite or probable virological failure at 12 months, compared with 19 (6.0%) and 40 (12.5%) with WHO-defined CD4 and clinical failure, respectively. CD4 criteria had a sensitivity of 21.2% and a specificity of 95.8% in detecting virological failure, and clinical criteria had sensitivity of 15.2% and specificity of 88.1%. The positive predictive value of CD4 and clinical criteria in detecting virological failure were 36.8 and 12.8%, respectively. Exclusion of weight loss or tuberculosis failed to improve the performance of clinical criteria. Conclusion:WHO clinical and CD4 criteria have poor sensitivity and specificity in detecting virological failure. The low specificities and positive predictive values mean that individuals with adequate virological suppression risk being incorrectly classified as having treatment failure and unnecessarily switched to second-line therapy. Virological failure should be confirmed before switching to second-line therapy.

[1]  R. Wood,et al.  Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study , 2008, BMC infectious diseases.

[2]  Sydney Rosen,et al.  Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review , 2007, PLoS medicine.

[3]  R. Chaiwarith,et al.  Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  R. Chaisson,et al.  Establishing a workplace antiretroviral therapy programme in South Africa , 2007, AIDS care.

[5]  B. Yip,et al.  Performance of Immunologic Responses in Predicting Viral Load Suppression: Implications for Monitoring Patients in Resource-Limited Settings , 2006, Journal of acquired immune deficiency syndromes.

[6]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[7]  B. Strom,et al.  Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy , 2006, AIDS.

[8]  D. Santoro,et al.  Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy: Evidence From the Italian Cohort of Antiretroviral-Naive Patients Study , 2006, Journal of acquired immune deficiency syndromes.

[9]  T. Quinn,et al.  A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. , 2006, The Lancet. Infectious diseases.

[10]  T. Flanigan,et al.  Lessons learned from use of highly active antiretroviral therapy in Africa. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Charalambous,et al.  Feasibility and acceptability of a specialist clinical service for HIV-infected mineworkers in South Africa , 2004, AIDS care.

[12]  A. Wu,et al.  Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature , 2002, Journal of acquired immune deficiency syndromes.

[13]  Jeffrey N. Martin,et al.  Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia , 2002, AIDS.

[14]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .